eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | open-angle glaucoma |
| Symptom | |intraocular pressure |
| Sentences | 65 |
| PubMedID- 25732405 | Brinzolamide 1 %/brimonidine 0.2 % ophthalmic suspension (simbrinza((r))) is a fixed-combination of a carbonic anhydrase inhibitor and an alpha2-adrenergic receptor agonist that is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension in both the usa and eu (with the eu indication restricted to patients for whom monotherapy provides insufficient iop reduction). |
| PubMedID- 22338465 | Objective: to evaluate changes of haemodynamic parameters in the retrobulbar arterial circulation after a decrease of elevated intraocular pressure (iop) in patients with primary open angle glaucoma (poag). |
| PubMedID- 20944938 | In bed and darkness for the diagnosis and intraocular pressure control of primary open-angle glaucoma. |
| PubMedID- 22668981 | intraocular pressure fluctuation in patients with primary open-angle glaucoma combined with high myopia. |
| PubMedID- 21905603 | The study was aimed at evaluating the efficacy of diode laser trabeculoplsaty in lowering intraocular pressure in patients with both primary open-angle glaucoma and exfoliation glaucoma by using different size of laser spot. |
| PubMedID- 24939513 | Purpose: to evaluate the long-term reproducibility of diurnal intraocular pressure (iop) patterns in patients with primary open-angle glaucoma (poag). |
| PubMedID- 20367989 | Background: elevation of intraocular pressure is usually associated with primary open angle glaucoma and caused by increased outflow resistance. |
| PubMedID- 20730536 | Bimatoprost is a synthetic prostamide, or prostaglandin ethanolamide, analog approved in 2001 for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (lumigan package insert, allergan, inc., 2006). |
| PubMedID- 20532144 | Brimonidine is a selective α-2-adrenergic agonist that has recently been approved for the long-term treatment of elevated intraocular pressure due to open angle glaucoma or ocular hypertension. |
| PubMedID- 23483493 | Purpose: to investigate relationships between blood pressure (bp), ocular perfusion pressure (opp), and intraocular pressure (iop) in patients with open-angle glaucoma (oag) of different body mass index (bmi) classes. |
| PubMedID- 25358880 | Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. |
| PubMedID- 22256559 | Purpose: the aim of the study was to evaluate the role of two potent and long-acting vasoconstrictors: endothelin-1 (et-1) and neuropetide y (npy) in the pathogenesis of glaucoma by: 1) measurement of plasma et-1 and npy concentrations in primary open-angle glaucoma (poag) patients with high intraocular pressure (htg patients) and with normal intraocular pressure (ntg patients) at baseline and following peripheral exposure to cold (cold-pressor test), 2) assessment whether changes, if any, in the plasma concentrations of both peptides following the cold-pressor test correlate with visual field defects. |
| PubMedID- 21526551 | Introduction/aim: argon laser trabeculoplasty (alt) is a recognized method for reducing intraocular pressure (iop) in patients with open angle glaucoma. |
| PubMedID- 25996599 | in addition, odh occurs up to 4 times more frequently in normal-tension glaucoma (ntg) than in primary open-angle glaucoma (poag) patients with baseline intraocular pressure (iop) of more than 21 mmhg. |
| PubMedID- 22798968 | Although the heterozygous s982nfsx4 mutation developed normal tension glaucoma, the homozygous nbce1 mutations usually developed open angle glaucoma with elevated intraocular pressure . |
Page: 1 2